Compare Medtronic PLC (MDT) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medtronic PLC vs Prudential PLC — how do they compare? Medtronic PLC trades at $88.24 (market cap $112.24B), while Prudential PLC trades at $23.92 (market cap $28.84B). The key difference: Medtronic PLC is far larger — about 3.9× Prudential PLC's market cap, and Medtronic PLC pays the higher dividend (3.28%). Which is the better fit depends on your goals — on Pluang, investors hold Medtronic PLC for 63 Days and Prudential PLC for 119 Days on average.
| MDT | PUK | |
|---|---|---|
Market Cap | $112.24B | $28.84B |
Volume | 105,663,236 | 3,531,298 |
Sector | Health | Financials |
52-Week High | $105.35 | $33.61 |
52-Week Low | $73.75 | $23.54 |
Typical Hold Time | 63 Days | 119 Days |
Enterprise Value | $131.58B | $28.38B |
Dividend Yield | 3.28% | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medtronic (MDT) trades at $87.80, up 2.68% today, with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with a 13.93% net income margin and consistent dividend growth over 49 years. Revenue growth accelerated to $33.54B in 2025, and analyst consensus targets $97.80, implying 11% upside. Recent news highlights regulatory approvals for medical devices and a $4B MiniMed exchange offer.
MDT offers value with a 3.2% dividend yield and reasonable valuation (P/E 21.6), but faces headwinds from technical bearishness and rising debt. The stock's appeal hinges on execution of growth initiatives in cardiovascular and neuroscience segments, though competitive and macroeconomic risks persist.
Prudential (PUK) trades at $23.87, up 1.38% with mixed technical signals showing bearish moving averages but oversold RSI levels. Fundamentally, the company demonstrates strong revenue growth from $16.2B in 2024 to $27.4B in 2025, with consistent profitability margins above 12%. Recent strategic moves include exiting emerging markets and focusing on core insurance operations while implementing a $3 billion capital rotation plan.
The outlook remains cautiously optimistic with 50% analyst buy ratings, though technical indicators suggest near-term pressure. Key risks include execution of strategic transitions and emerging market exposure reductions. The stock presents value characteristics with an 8.4 P/E ratio while maintaining dividend distributions, though investors should monitor earnings consistency after recent misses.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Medtronic PLC
One of the largest medical device companies, Medtronic develops and manufactures therapeutic medical devices for chronic diseases. Its portfolio includes pacemakers, defibrillators, heart valves, stents, insulin pumps, spinal fixation devices, neurovascular products, advanced energy, and surgical tools. The company markets its products to healthcare institutions and physicians in the United States and overseas. Foreign sales account for almost 50% of the company's total sales.
Read more on MDT →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
